髓鞘少突胶质细胞糖蛋白抗体相关性疾病研究进展  

Advances in myelin oligodendrocyte glycoprotein antibody-associated disease

作　　者：徐华(综述)[1] 王纪文(审校) Xu Hua;Wang Jiwen(Shanghai Children′s Medical Center,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属上海儿童医学中心,200127

出　　处：《国际儿科学杂志》2022年第5期302-306,共5页International Journal of Pediatrics

摘　　要：髓鞘少突胶质细胞糖蛋白抗体相关性疾病(myelin oligodendrocyte glycoprotein antibody-associated disease,MOGAD)是中枢神经系统炎性脱髓鞘疾病之一。由于MOGAD临床表型谱多样且非典型,依据目前的检测方法阳性率不高,早期诊断困难。该综述旨在阐述MOGAD的流行病学、发病机制、临床特点、诊断标准、生物学标记、治疗及预后等研究进展,以提高临床医生对此病的认识,从而早期识别、尽早治疗、减少复发。Myelin oligodendrocyte glycoprotein antibody-associated disease(MOGAD)is one of inflammatory demyelinating disorders of the central nervous system.Due to the diverse and atypical clinical manifestations,positive rate of current detection methods is not high,and early diagnosis is difficult.This review aims to elucidate the research progress of the epidemiology,pathogenesis,clinical characteristics,diagnostic criteria,biological markers,treatment and prognosis of MOGAD,in order to improve the understanding of MOGAD for clinicians,so as to identify,treat and reduce the recurrence of MOGAD as early as possible.

关 键 词：髓鞘少突胶质细胞糖蛋白抗体相关性疾病 炎性脱髓鞘疾病 发病机制 

分 类 号：R73[医药卫生—肿瘤]